Clinical Research Directory
Browse clinical research sites, groups, and studies.
Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
Sponsor: Nanjing First Hospital, Nanjing Medical University
Summary
This study aims to compare the efficacy and safety of keverprazan-minocycline dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication, focusing on eradication rates, patient adherence, and the incidence of adverse drug reactions.
Official title: Efficacy and Safety of Keverprazan-minocycline Dual Therapy With Different Treatment Durations Versus Bismuth-based Quadruple Therapy for Helicobacter Pylori Eradication: an Open-label, Multicenter, Randomized, Non-inferiority Trial.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
612
Start Date
2026-07-15
Completion Date
2027-12-30
Last Updated
2026-10-29
Healthy Volunteers
No
Conditions
Interventions
Minocycline
100 mg oral capsule, twice daily
Keverprazan
20 mg oral tablet, twice daily
Amoxicillin
1000 mg oral tablet, twice daily
Colloidal Bismuth Pectin
300 mg oral preparation, twice daily
Locations (1)
Nanjing First Hospital
Nanjing, Jiangsu, China